Prostate cancer is the uncontrolled growth of cells in the prostate gland. It is one of the most commonly seen cancers in men and can often be treated successfully.
The prostate gland is a small, walnut-shaped organ found only in men, which produces the seminal fluid for nourishment and transportation of sperm.
Prostate cancer arises from the gland cells that make prostate fluid that is added to the semen. Prostate adenocarcinomas are the most common forms of prostate cancer. They can either be acinar adenocarcinomas (cancer of the gland cells that line the prostate gland) or ductal adenocarcinomas (cancer of cells that line the ducts or tubes of the prostate gland).
Other types of prostate cancer include:
Some prostate cancers grow slowly and require regular monitoring. However, other types of prostate cancer are aggressive and need immediate treatments.
In the early stages of prostate cancer, there may be no signs or symptoms. However, in advanced stages, men may experience following signs and symptoms:
While there are no definitive causes, some factors that can increase the chances of developing prostate cancer include:
Consult a urologist if any signs or symptoms bother you. You may be referred to an oncologist if required. Diagnostic tests for prostate cancer might include:
– Medical history
– Examination and screening:
After identifying prostate cancer, doctors try to figure out its size and extent of spread. This process is called the staging of prostate cancer. It also helps the oncologist to decide the treatment plan.
Cancer staging is done in two ways: TNM (Tumour, Node, Metastasis) staging and Number staging from 1 to 4.
Prostate-specific antigen (PSA) is a protein secreted by the prostate gland. Some conditions such as prostatitis, benign prostatic hyperplasia (enlarged prostate) and prostate cancer result in elevated PSA levels in the body. Thus, the PSA level is one among the other tools that are used for staging prostate cancer. PSA level in the range of 4 to 10 ng/mL is suspicious and doctors may suggest screening for prostate cancer.
Stage 1: The cancer is localized and has not spread to lymph nodes. The PSA level is less than 10 and graded as group 1.
Stage 2: The cancer is localized and has not spread outside the prostate or lymph nodes. The PSA level is less than 20. The prostate cancer stage 2A, stage 2B, and stage 2C are graded as group 1, group 2 and group 3 or 4, respectively.
Stage 3: In stage 3A, the cancer is confined within the prostate and the PSA value is at least 20. As cancer progresses to stage 3B, it grows into the seminal vesicles and surrounding tissues such as the urethral sphincter, rectum, bladder and/or wall of the pelvis. However, in stage 3, cancer has not yet spread to the lymph nodes. The grade group of prostate cancer at stage 3A and stage 3B are group 1 to 4; at stage 3C it is group 5.
Stage 4: In stage 4A, cancer has spread to the lymph nodes but cancer has not spread elsewhere in the body. As cancer progresses to stage 4B, it spreads to other, distant parts of the body. The grade group and PSA value vary broadly.
The treatment options for prostate cancer are based on the type and stage of prostate cancer and other factors like overall health, age, and sensitivity to certain medications.
Active surveillance includes regular follow-up with blood tests, rectal examinations, and biopsy, if required, to evaluate and monitor the progression of prostate cancer.
The conservative approaches include:
Radical prostatectomy: Radical prostatectomy is a major surgery recommended by doctors for patients with prostate cancer. In this surgery, the prostate gland and the surrounding tissue with some lymph nodes are removed. The surgery can be performed in the following ways:
robot-assisted prostatectomy, the surgery is done using a robotic system. During the surgery, the surgeon uses the control panel in the operating room to move the robotic arms and operate through several small incisions (cuts) in the patient’s abdomen. The robotic arms allow freedom of motion similar to the surgeon’s hand; an improvement over the traditional laparoscopic tools.
Survival rates are often used by doctors to determine the patient’s prognosis. The 5-year survival rate implies the percentage of people surviving 5 years after the diagnosis of their disease. It depends on many factors like the overall health of the patient, stage, and site of the tumor.
The 5-year relative survival rate for local stage prostate cancer is 100% (stage 0 – 3). About 4 out of 5 prostate cancers are diagnosed in these stages.
The 5-year relative survival rate for regional stage prostate cancer is 100% (stage 3B and 4A).
The 5-year relative survival rate for regional stage prostate cancer is 29% (stage 4B).
Even though there are no certain causes, the risk for prostate cancer can be reduced by engaging in
To know more about prostate cancer and its treatment, you can request a callback and our prostate cancer specialist will call you and answer all your queries.
Sr. Consultant Radiation Oncologist , Clinical Director.
Clinical Director-Surgical Oncology, Sr. Consultant Surgical Oncology and Robotic Surgical Oncology
Sr. Consultant Medical Oncologist &
Hematologist
Sr. Consultant Radiation Oncologist Clinical Director
Sr. Consultant Surgical Oncologist,
Minimal Invasive & Robotic Surgeon
Consultant Medical Oncologist
Consultant Medical Oncologist
Consultant Surgical Oncologist, Minimal Invasive Onco Surgeon
Sr. Consultant Radiation Oncologist
Consultant Radiation Oncologist
Director-Oncology Services, Consultant Medical Oncologist & Hemato Oncologist
Consultant Radiation Oncologist
Consultant Surgical Oncologist
Consultant Radiation Oncologist
Consultant Surgical Oncologist
Minimal Invasive Surgeon
Consultant Medical Oncologist & Hemato Oncologist
Senior Consultant Hematologist & Medical Oncologist
Clinical Director- Medical Oncology & Haematology
Consultant Radiation Oncologist
Director-Surgical Oncology & Minimal Access Onco Surgery and Robotic Surgeon
Sr. Consultant-Surgical Oncology, Laparoscopic & Robotic Surgery, HIPEC Surgery (Germany)
Sr. Consultant Medical Oncologist & Haemato Oncologist
Consultant Radiation Oncologist
Sr. Consultant Medical & Hemato-Oncologist
Consultant Radiation oncologist
Consultant Radiation Oncologist
Sr. Consultant Radiation Oncologist
Sr. Consultant Surgical Oncologist
Clinical Director & HOD, Medical Oncology Sr. Consultant, Medical Oncology & Hemato-Oncology
Sr. Consultant Radiation Oncologist
Sr. Consultant Surgical Oncologist & Robotic Surgeon(Cancer Specialist) Clinical Director
Consultant Radiation Oncologist
Consultant Radiation Oncology
Sr. Consultant Medical Oncologist and Hemato-Oncologist
Consultant Surgical Oncologist
Consultant Radiation Oncologist
Disclaimer: The content of this publication has been developed by a third party content provider who is clinicians and/or medical writers and/or experts. The information contained herein is for educational purpose only and we request you to please consult a Registered Medical Practitioner or Doctor before deciding the appropriate diagnosis and treatment plan.
Talk to Our Health Care Experts!
Appointment
Second Opinion
Live Chat
Call
More
